Cargando…
A cost‐effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first‐line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan
BACKGROUND: Patients with locally advanced or metastatic urothelial carcinoma have limited treatment options and a poor prognosis. The JAVELIN Bladder 100 trial showed that avelumab as first‐line maintenance plus best supportive care significantly prolonged overall survival and progression‐free surv...
Autores principales: | Su, Po‐Jung, Xiao, Ying, Lin, Amy Y., Goh, Connie, Wu, Ethan, Liu, Kevin, Chou, Patrick, Kuo, Kaitlin, Palencia, Roberto, Chang, Jane, Kearney, Mairead, Kapetanakis, Venediktos, Benedict, Agnes |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598249/ https://www.ncbi.nlm.nih.gov/pubmed/37640556 http://dx.doi.org/10.1002/cnr2.1887 |
Ejemplares similares
-
Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma
por: Xie, Qian, et al.
Publicado: (2022) -
Corrigendum: Cost-effectiveness of avelumab maintenance therapy plus best supportive care vs. best supportive care alone for advanced or metastatic urothelial carcinoma
por: Xie, Qian, et al.
Publicado: (2022) -
Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
por: Tomita, Yoshihiko, et al.
Publicado: (2022) -
A cost‐utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan
por: Chang, Wen‐Cheng, et al.
Publicado: (2021) -
Decision-making factors for best supportive care alone and prognostic factors after best supportive care in non-small cell lung cancer patients
por: Kitazawa, Haruna, et al.
Publicado: (2019)